ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: INFO16-TH

Intensified Acute Kidney Disease Care to Reduce CKD: ISACC Trial

Session Information

  • Informational Posters - I
    November 07, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

Authors

  • Chen, Yu-Wei, Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
  • Hsu, Yung-Ho, Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
  • Wu, Mai-Szu, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan

Group or Team Name

  • The EIRAP (Epidemiology, Injury, Repair, Artificial intelligence and Policy) study group
Description

Acute kidney disease (AKD), defined as the ongoing renal function impairment between 7 days and 90 days following AKI, has been proposed as a window of intervention to prevent the occurrence of CKD. However, the effective therapeutic strategies of AKD care remain to be developed. We intend to conduct a prospective, randomized, open-label, behavioral interventional trial (Figure 1) to validate the efficacy of multidiscipline team (MDT) care model which aims to improve AKD care and to reduce de novo CKD incidence.

Study design
Study Type: Interventional (Clinical Trial)
Estimated Enrollment:690
Allocation: Randomized
Blinding: None (Open Label)
Study start date:2020/1/1
Estimated Primary Completion Date:2020/12/31

Arms and Interventions
Arm1
Experimental: Multidisciplinary team (MDT) care + Acute kidney disease (AKD) clinic (Figure2A and 2B)
Participants randomized to this arm will receive the multidisciplinary team (MDT) care by a specialized medical team which is composed of nephrologist, pharmacist, and dietitian. Post-discharge acute kidney disease (AKD) clinic will also be arranged for them.
Arm2
No Intervention: Usual care
Nephrologist consultation and nephrology outpatient clinic follow-up will be allowed. However, this group of patients will not have access to MDT care and AKD clinic.

Criteria
Inclusion criteria:
(1)Age ≥ 20 yrs
(2)Severe AKI: Stage 2, Stage 3 and Dialysis-requiring AKI (AKI-D) by KDIGO staging
Exclusion criteria:
(1)Pregnancy

Primary composite outcome:
Proportion of MAKE
-Renal progression to CKD
-Chronic dialysis
-Death

Preliminary data: Algorithm for detection of AKI, AKD and CKD has successfully identified 6% of AKI among 46374 patients in 2016. Prevalence of stage 5 CKD increased from 5% (baseline) to 9% (90days after AKI).

Funding

  • Applying for the Thematic Research Grant (TRG) from the National Health Research Institutes (NHRI) in Taiwan, ROC